Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajo.2024.06.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A diagnostic dilemma for a patient with skin lesions and marked leukocytosis: mixed-phenotype acute leukaemia or blastic plasmacytoid dendritic cell neoplasm with aberrant cytoplasmic CD3 expression?
Pathology
November 2024
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:
Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.
Clin Pathol
December 2024
Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, CA, USA.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive neoplastic process of precursor plasmacytoid dendritic cells. The diagnostic evaluation of this heterogenous entity is challenging, requiring a comprehensive approach of incorporating clinical, morphologic, immunohistochemical, and molecular/cytogenetic evaluations. Optimal management of BPDCN remains controversial, and clinical outcomes continues to be poor.
View Article and Find Full Text PDFBlastic plasmacytoid dendritic cell neoplasm in the chest: Report of a rare case.
Asian J Surg
December 2024
Department Care Unit, Hebei Yanda Lu Daopei Hospital, Langfang, 065201, Hebei Province, China. Electronic address:
BPDCN: state of the art.
Hematology Am Soc Hematol Educ Program
December 2024
Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX.
Article Synopsis
Venetoclax-Proteasome inhibitor-Dexamethasone for unfit patients with Blastic Plasmacytoid Dendritic Cell Neoplasm.
Blood Adv
December 2024
Gustave Roussy, Villejuif, France.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!